Monday, December 13, 2010
Arena Pharmaceuticals Inc., of San Diego, started dosing in a Phase I trial of APD811, an oral candidate designed to target the prostacyclin receptor for treatment of pulmonary arterial hypertension. The study is expected to enroll up to 72 healthy adult volunteers to test single-ascending doses of the drug.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.